XTLB

XTL Biopharmaceuticals
XTLB

6 hedge funds and large institutions have $191K invested in XTL Biopharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.

Upgrade to unlock
New
Increased
Maintained
Reduced
Closed

more first-time investments, than exits

New positions opened: | Existing positions closed:

more funds holding

Funds holding: →

more repeat investments, than reductions

Existing positions increased: | Existing positions reduced:

less ownership

Funds ownership: →

28% less capital invested

Capital invested by funds: $266K → $191K (-$74.9K)

Holders
6
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
–
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
–
Puts
–
Net Calls
Net Calls Change

Top Buyers

1
+$76.8K
2
+$13K
3
+$13K
4
XT
XTX Topco
Cayman Islands
+$10.4K

Top Sellers

1
-$8.37K
2
-$893
Name Holding Trade Value Shares
Change 		Change in
Stake
NI
1
Noked Israel
Israel
$115K
Citadel Advisors
2
Citadel Advisors
Florida
$44K
RhumbLine Advisers
3
RhumbLine Advisers
Massachusetts
$17.5K
GI
4
GAMMA Investing
California
$7.47K
XT
5
XTX Topco
Cayman Islands
$5.94K
Morgan Stanley
6
Morgan Stanley
New York
$1.01K
UBS Group
7
UBS Group
Switzerland
–